SCHEMBL17309377

SCHEMBL17309377

CCOc1cc(/C=C2\S/C(=N\c3ccc(F)cc3)N(c3ccc(F)cc3)C2=O)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 5/20 1.00
▸ MEN1 O00255 8/20 0.77
▸ KMT2A Q03164 8/20 0.77
▸ BLM P54132 1/20 0.77
▸ NPSR1 Q6W5P4 1/20 0.77
▸ MAPT P10636 7/20 0.67
▸ SMN1; SMN2 Q16637 1/20 0.67
▸ ITGB3 P05106 1/20 0.64
▸ ITGAV P06756 1/20 0.64
▸ ALDH1A1 P00352 2/20 0.62
▸ LMNA P02545 2/20 0.62
▸ IDE P14735 2/20 0.58
▸ POLB P06746 1/20 0.58
▸ HTT P42858 1/20 0.58
▸ CA9 Q16790 1/20 0.57
▸ MCL1 Q07820 1/20 0.56
▸ S1PR1 P21453 2/20 0.51
▸ S1PR3 Q99500 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17309315 1.00 FAAH (1.00) FAAHMEN1KMT2ABLMNPSR1
SCHEMBL19481522 0.92 FAAH (0.84) FAAHMEN1KMT2ABLMNPSR1
SCHEMBL19485870 0.92 FAAH (0.84) FAAHMEN1KMT2ABLMNPSR1
SCHEMBL17309278 0.90 FAAH (0.82) FAAHMEN1KMT2ABLMNPSR1
SCHEMBL1641528 0.86 MEN1 (0.84) FAAHMEN1KMT2ABLMNPSR1
SCHEMBL1421174 0.86 MEN1 (0.84) FAAHMEN1KMT2ABLMNPSR1
SCHEMBL1421482 0.85 FAAH (0.73) FAAHMEN1KMT2ABLMNPSR1
SCHEMBL1421478 0.85 FAAH (0.73) FAAHMEN1KMT2ABLMNPSR1
SCHEMBL17309313 0.83 FAAH (0.77) FAAHMEN1KMT2ABLMNPSR1
SCHEMBL19481527 0.82 MAPT (0.80) FAAHMEN1KMT2ABLMNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3148541-B1 THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION UNIV BERN (CH) 2020-09-02 — — EP disclosed
US-10300048-B2 Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation UNIVERSITAT BERN (CH) 2019-05-28 — — US disclosed
US-20170296515-A1 THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION UNIVERSITAT BERN (CH) 2017-10-19 — — US disclosed
US-20170296515-A1 THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION UNIVERSITAT BERN (CH) 2017-10-19 — — US disclosed
EP-2952188-A1 Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation Universität Bern (CH) 2015-12-09 — — EP disclosed
WO-2015181336-A1 THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION Universität Bern (CH) 2015-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10300048-B2 Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation SLC18A2, AANAT, CNR2 FAAH 27/4885MEN1 4253/4885KMT2A 2455/4885
US-20170296515-A1 THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION SLC18A2, AANAT, CNR2 FAAH 27/4885MEN1 4253/4885KMT2A 2455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback